Drug intelligence / Profile preview

okra extract

Development stage: Preclinical
Lead developer: Zocular
Modality: Small Molecules
Administration: Ophthalmic, Oral

Overview

Okra extract, derived from Abelmoschus esculentus, is rich in mucilage, polysaccharides, and antioxidants. It is being investigated for its therapeutic potential, particularly in conditions like dry eye, where its anti-inflammatory, antioxidant, and moisturizing properties are beneficial. It is also recognized for its nutraceutical importance, supporting heart health, gut health, and providing overall antioxidant support.

Other names: 秋葵眼贴okra mucilage

Targets

LDLR (Low-density lipoprotein receptor)

Beyond the preview

Go deeper on okra extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on okra extract.

Explore the full profile